Table 1 Patient demographics at baseline
From: Tolerance and rebound with zafirlukast in patients with persistent asthma
β2-agonists + Placebo (N = 7) | β2-agonists + Zafirlukast (N = 14) | ICS-treated + Placebo (N = 8) | ICS-treated + Zafirlukast (N = 16) | |
|---|---|---|---|---|
Sex, male/female | 3/4 | 8/6 | 2/6 | 9/7 |
Age, years | 29 (21–55) | 42 (21–69) | 45 (30–65) | 37 (19–65) |
Ex-smoker | 2 | 4 | 5 | 6 |
FEV1, L | 2.7 (2.3–3.7) | 2.1 (1.4–4.2) | 2.8 (2.0–3.8) | 2.7 (1.4–4.1) |
Baseline FEV1, % predicted | 80 (65–102) | 85 (69–107) | 76 (60–95) | 77 (56–98) |
Inhaled corticosteroid, μg/day | NA | NA | 1600 (1000–2400) | 1600 (1000–2400) |
PD20 methacholine, μg * | 0.008 (0.001–0.04) | 0.04 (0.005–1.3) | 0.03 (0.004–0.2) | 0.02 (0.001–0.6) |